who should not take glp 1 receptor agonists Mapping the effectiveness and risks of GLP-1 GLP-1 Receptor Agonist Use Is

doi: 10.3390/ijms21165722

Myra Ahmad, told EMARKETER that drug personalization is needed for patients who may require a lower dose or a different formulation due to experiencing side effects

Will the oral GLP-1 pill be safe long-term

77 A meta-analysis of 76 RCTs, involving over 100,000 adults with overweight, obesity, or type 2 diabetes found that GLP-1 RA treatment, compared to placebo or other active comparators, was associated with a modestly elevated risk of cholelithiasis (RR: 1.27, 95% CI 1.10, 1.47), cholecystitis (RR: 1.36, 95% CI 1.14, 1.62), and overall biliary disease (RR: 1.55, 95% CI 1.08, 2.22), corresponding to an absolute increase of approximately 27 events per 10,000 patients per year

www.fda.gov/Drugs/DrugSafety/ucm459579.htm